Condition: Acromegaly · Sponsor: Debiopharm International SA
The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.
This description comes directly from the study's public registry record.
Debiopharm International S.A · +41 21 321 01 11 · clinicaltrials@debiopharm.com
Always discuss trial participation with your own doctor first.
| Cedars Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Harvard Medical School | Boston, Massachusetts, United States | Recruiting |
| Washington University-School of Medicine | St Louis, Missouri, United States | Recruiting |
| Palm Research Center Inc | Las Vegas, Nevada, United States | Recruiting |
| NYU Grossman School of Medicine | New York, New York, United States | Not Yet Recruiting |
| The Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| The Ohio State University | Columbus, Ohio, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
| Thomas Jefferson University | Philadelphia, Pennsylvania, United States | Recruiting |
| Medical University Graz | Graz, Austria | Recruiting |
| Medizinische Universitaet Wien - Division of Endocrinology and Metabolism | Vienna, Austria | Recruiting |
+ 60 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06930625